Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
Biohaven Pharmaceuticals (NYSE: BHVN) celebrated the FDA approval of its migraine treatment by ringing the opening bell at the New York Stock Exchange on June 8, 2021. This event coincided with Migraine and Headache Awareness Month, highlighting the significance of their breakthrough medication, which is the first and only approved solution for treating and preventing migraines. The company aims to support the migraine community, reflecting its commitment to addressing this prevalent health issue.
- FDA approval of the first and only medicine to treat and prevent migraines.
- Public awareness initiative coinciding with Migraine and Headache Awareness Month.
- None.
A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine.
BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine. (Photo: NYSE)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005948/en/
FAQ
What milestone did Biohaven Pharmaceuticals celebrate on June 8, 2021?
What significant event coincided with the opening bell ceremony for Biohaven?
What is the stock symbol for Biohaven Pharmaceuticals?
